Education
About Us
Working with TipRanks
Follow Us
Merus NV (MRUS)
NASDAQ:MRUS
MRUS Analyst Ratings
Strong Buy
14 Buy
0 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
MRUS Stock 12 Month Forecast
Average Price Target
$97.00
▲(42.27% Upside)
| Highest Price Target$112.00 | Average Price Target$97.00 | Lowest Price Target$67.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Bank of America Securities
$92
Buy
34.94%
Upside
Reiterated
09/15/25
Guggenheim
$109
Buy
59.87%
Upside
Reiterated
09/12/25
LifeSci Capital
$110
Buy
61.34%
Upside
Reiterated
09/12/25
Merus's Oncology Potential and Financial Stability Justify Buy Ratings: We checked-in with MRUS mgmt to discuss upcoming near-term updates for petosemtamab in 1L, 2L, and 3L+ RAS/RAF- wildtype CRC (see also Petosemtamab CRC 2H 2025 Earnings Catch-Up). Mgmt has remained consistent in their messaging on exisng CR C benchmarks, while acknowledging nuances in data interpretaon such as pa en t baseline characteriscs. Giv en the early nature of upcoming data, mgmt noted that their confidence in "inferring from ORR to me-t o-event endpoints" is an important queson. W e also asked on paen t baseline characteriscs & pot enal treatment histories of 2L paen ts, given the availability and possible preference for EGFR inhibitors in 1L RAS/RAF-wildtype paen ts, especially those with le -sided tumors.
Alliance Global Partners
$90
Buy
32.00%
Upside
Initiated
08/25/25
Canaccord Genuity
$67
Buy
-1.73%
Downside
Reiterated
08/14/25
Needham
$97→$96
Buy
40.80%
Upside
Reiterated
08/06/25
Wells Fargo
$89→$95
Buy
39.34%
Upside
Reiterated
08/06/25
Leerink Partners
$95
Buy
39.34%
Upside
Reiterated
08/06/25
H.C. Wainwright
$85
Buy
24.67%
Upside
Reiterated
08/06/25
William Blair
―
Buy
―
Reiterated
08/06/25
Truist Financial
―
Buy
―
Reiterated
06/02/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Bank of America Securities
$92
Buy
34.94%
Upside
Reiterated
09/15/25
Guggenheim
$109
Buy
59.87%
Upside
Reiterated
09/12/25
LifeSci Capital
$110
Buy
61.34%
Upside
Reiterated
09/12/25
Merus's Oncology Potential and Financial Stability Justify Buy Ratings: We checked-in with MRUS mgmt to discuss upcoming near-term updates for petosemtamab in 1L, 2L, and 3L+ RAS/RAF- wildtype CRC (see also Petosemtamab CRC 2H 2025 Earnings Catch-Up). Mgmt has remained consistent in their messaging on exisng CR C benchmarks, while acknowledging nuances in data interpretaon such as pa en t baseline characteriscs. Giv en the early nature of upcoming data, mgmt noted that their confidence in "inferring from ORR to me-t o-event endpoints" is an important queson. W e also asked on paen t baseline characteriscs & pot enal treatment histories of 2L paen ts, given the availability and possible preference for EGFR inhibitors in 1L RAS/RAF-wildtype paen ts, especially those with le -sided tumors.
Alliance Global Partners
$90
Buy
32.00%
Upside
Initiated
08/25/25
Canaccord Genuity
$67
Buy
-1.73%
Downside
Reiterated
08/14/25
Needham
$97→$96
Buy
40.80%
Upside
Reiterated
08/06/25
Wells Fargo
$89→$95
Buy
39.34%
Upside
Reiterated
08/06/25
Leerink Partners
$95
Buy
39.34%
Upside
Reiterated
08/06/25
H.C. Wainwright
$85
Buy
24.67%
Upside
Reiterated
08/06/25
William Blair
―
Buy
―
Reiterated
08/06/25
Truist Financial
―
Buy
―
Reiterated
06/02/25
Best Analysts Covering Merus
1 Month
xxx
Success Rate
6/9 ratings generated profit
Average Return
+3.26%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 66.67% of your transactions generating a profit, with an average return of +3.26% per trade.
3 Months
xxx
Success Rate
8/9 ratings generated profit
Average Return
+13.12%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 88.89% of your transactions generating a profit, with an average return of +13.12% per trade.
1 Year
Success Rate
9/10 ratings generated profit
Average Return
+32.88%
reiterated a buy rating last month
Copying John Newman's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +32.88% per trade.
2 Years
xxx
Success Rate
28/28 ratings generated profit
Average Return
+100.28%
reiterated a xxx
rating last month
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +100.28% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
MRUS Analyst Recommendation Trends
Rating
May 25
Jun 25
Jul 25
Aug 25
Sep 25
Strong Buy
28
28
26
8
7
Buy
14
17
15
14
12
Hold
12
10
7
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
54
55
48
24
20
Each month's total comprises the sum of three months' worth of ratings.
MRUS Financial Forecast
MRUS Stock Forecast FAQ
What is MRUS’s average 12-month price target, according to analysts?
Based on analyst ratings, Merus NV’s 12-month average price target is 97.00.
What is MRUS’s upside potential, based on the analysts’ average price target?
Merus NV has 42.27% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is MRUS a Buy, Sell or Hold?
Merus NV has a consensus rating of Strong Buy which is based on 14 buy ratings, 0 hold ratings and 0 sell ratings.
What is Merus NV’s price target?
The average price target for Merus NV is 97.00. This is based on 14 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $112.00 ,the lowest forecast is $67.00. The average price target represents 42.27% Increase from the current price of $68.18.
The highest analyst price target is $112.00 ,the lowest forecast is $67.00. The average price target represents 42.27% Increase from the current price of $68.18.
What do analysts say about Merus NV?
Merus NV’s analyst rating consensus is a Strong Buy. This is based on the ratings of 14 Wall Streets Analysts.
How can I buy shares of MRUS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.